CSL
CSL downgrading revenue (by a few percentage points) and NPATA guidance by around 3% (7%-10% is now 4%-7% at constant currency).
Those Americans choosing to not get vaccinated are weighing further on the outlook.

Management are at some pains to explain that the Behring business is going well. That is perhaps modest comfort, given that at the August result many were concerned about the IVIG portfolio (where sales had declined in the half). It sounds like things are either better, there.

Still, a downgrade is a downgrade, and unlikely to be warmly received by the market. Seqirus seeing vaccination rates down by double digits.

Management now expects this negative sentiment (towards vaccines, or the need to be vaccinated) to be with us for a while, which makes sense. As long as RFK is a part of the HHS, the views coming from the top are likely to be broadly negative. He won’t be there forever, but it does feel like CSL’s journey towards better days is long, and certainly longer than we’d anticipated or wanted.
Important Information: This document has been prepared by Aequitas Investment Partners Pty Ltd ABN 92 644 165 266 (“Aequitas”, “our”, “we”), a Corporate Authorised Representative (no. 1284389) of AIP FS Pty Ltd ABN 49 680 982 478 (Australian Financial Services Licensee no. 700016) and is for distribution within Australia to wholesale clients only.
This document is based on information available at the time of publishing, information which we believe is correct and any opinions, conclusions or forecasts are reasonably held or made as at the time of its compilation, but no warranty is made as to its accuracy, reliability or completeness. To the extent permitted by law, neither Aequitas nor any of its affiliates accept liability to any person for loss or damage arising from the use of the information herein.
Past performance is not a reliable indicator of future performance.
General Advice Warning: This document has been prepared without taking into account your objectives, financial situation or needs, and therefore you should consider its appropriateness, having regard to your objectives, financial situation and needs. Before making any decision about whether to acquire a financial product, you should obtain and read the relevant Product Disclosure Statement (PDS) or Investor Directed Portfolio Service Guide (IDPS Guide) and consider talking to a financial adviser.
Taxation warning: Aequitas is not authorised to provide tax (financial) advice and is not a registered tax agent. Investors should seek their own tax advice from a registered tax agent or a registered tax (financial) adviser if they intend to rely on this information to satisfy the liabilities or obligations or claim entitlements that arise, or could arise, under a taxation law. We recommend that you consult a registered tax agent or a tax specialist to confirm your taxation position.